Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Mid Atlantic Retina

Neither a doctor nor a teaching hospital

Research payments

$6,072,586

700 payments

Through program year 2025, Mid Atlantic Retina is reported as receiving $6,072,586 in research payments, across 700 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $694,112 291
2024 Research $432,301 82
2023 Research $1,160,630 41
2022 Research $1,421,057 96
2021 Research $960,789 81
2020 Research $750,227 56
2019 Research $653,470 53

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $1,860,329 121 payments
  2. Apellis Pharmaceuticals, Inc. $1,787,646 83 payments
  3. Regeneron Pharmaceuticals, Inc. $820,603 268 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $686,214 56 payments
  5. Novartis Pharmaceuticals Corporation $499,285 15 payments
  6. Kyowa Kirin, Inc. $295,925 77 payments
  7. Roche TCRC, Inc. $32,218 3 payments
  8. Alcon Research LLC $30,108 4 payments
  9. Gilead Sciences, Inc. $25,752 11 payments
  10. Boehringer Ingelheim Pharma GmbH & Co.KG $23,699 52 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD $621,359 24 payments
  2. Port Delivery System for Ranibizumab $490,156 16 payments
  3. An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD $362,182 19 payments
  4. A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) $335,103 139 payments
  5. A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema $295,925 77 payments
  6. Va2 Phiii $260,937 16 payments
  7. A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration $259,293 13 payments
  8. BAY865321 HD 8mg AMD - Ph 3 $244,783 6 payments
  9. A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration $240,551 10 payments
  10. A Multicenter Randomized Double Masked Phase 3A Study to Assess Safety and Efficacy of Brolucizumab 6 MG Q4 Weeks Compared to Aflibercept 2 MG Q4 Weeks in Patients With Neovascular Age Related MacUlar Degeneration Namd With Persistent Retinal Fluid $233,842 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record